Related Experiment Video

Updated: Jun 25, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Vascular and metabolic effects of angiotensin II receptor blockers

Silvia Barra1, Alice Vitagliano, Vittoria Cuomo

  • 1Antonio Cardarelli Hospital, Cardiology Unit, 9, Via Antonio Cardarelli, 80131 Napoli, Naples, Italy.

Expert Opinion on Pharmacotherapy
|February 25, 2009
PubMed

Insights

Angiotensin II receptor blockers (ARBs) offer cardiovascular benefits beyond blood pressure reduction, including anti-inflammatory and vascular effects. While ARBs show promise, their impact on type 2 diabetes mellitus risk and varying potencies require further investigation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Endocrinology

Background:

  • Angiotensin II receptor blockers (ARBs) are frequently prescribed for hypertension, heart failure, and type 2 diabetes mellitus (T2DM).
  • Clinical trials confirm ARBs reduce cardiovascular mortality and morbidity, with benefits extending beyond blood pressure lowering.
  • These advantages are attributed to ARBs' anti-inflammatory, metabolic, and vascular effects, potentially linked to dosage and treatment duration.

Purpose of the Study:

  • To review the multifaceted benefits of ARBs in cardiovascular disease management.
  • To explore the non-hemodynamic effects of ARBs, including their impact on inflammation, metabolism, and vascular health.
  • To assess the evidence regarding ARBs' influence on new-onset T2DM and vascular remodeling.

Main Methods:

  • Systematic review of large clinical trials and studies on ARBs.
  • Analysis of data concerning cardiovascular outcomes, metabolic effects, and vascular changes associated with ARB therapy.
  • Evaluation of specific ARBs' effects, such as losartan's impact on uric acid levels.

Main Results:

  • ARBs demonstrate significant reductions in cardiovascular mortality and morbidity.
  • Benefits include anti-inflammatory actions, improvement in endothelial dysfunction, and regression of vascular hypertrophy.
  • ARBs' effect on reducing new-onset T2DM risk is inconsistent; only losartan consistently lowered serum uric acid.

Conclusions:

  • ARBs provide substantial cardiovascular protection through mechanisms beyond blood pressure reduction.
  • Positive vascular effects and metabolic improvements contribute to enhanced patient outcomes.
  • Further research is needed to clarify the clinical significance of varying ARB potencies and their specific roles in disease management.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...